Table of Contents Author Guidelines Submit a Manuscript
Journal of Nucleic Acids
Volume 2012 (2012), Article ID 707323, 7 pages
http://dx.doi.org/10.1155/2012/707323
Research Article

Superior Silencing by 2′,4′-BNANC-Based Short Antisense Oligonucleotides Compared to 2′,4′-BNA/LNA-Based Apolipoprotein B Antisense Inhibitors

1Applied Biopharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan
2Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan
3BNA Inc, 7-7-20 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan

Received 13 June 2012; Revised 17 August 2012; Accepted 18 August 2012

Academic Editor: Masayasu Kuwahara

Copyright © 2012 Tsuyoshi Yamamoto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. R. Rayburn and R. Zhang, “Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?” Drug Discovery Today, vol. 13, no. 11-12, pp. 513–521, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Yamamoto, M. Nakatani, K. Narukawa, and S. Obika, “Antisense drug discovery and development,” Future Medicinal Chemistry, vol. 3, no. 3, pp. 339–365, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Akdim, M. E. Visser, D. L. Tribble et al., “Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia,” American Journal of Cardiology, vol. 105, no. 10, pp. 1413–1419, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. E. Visser, J. J. P. Kastelein, and E. S. G. Stroes, “Apolipoprotein B synthesis inhibition: results from clinical trials,” Current Opinion in Lipidology, vol. 21, no. 4, pp. 319–323, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. T. S. Crooke, Antisense Drug Technologies: Principles, Strategies, and Applications, CRC Press, 2007.
  6. E. E. Swayze, A. M. Siwkowski, E. V. Wancewicz et al., “Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals,” Nucleic Acids Research, vol. 35, no. 2, pp. 687–700, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. M. H. -S. Tsuyoshi Yamamoto, M. Nakatani, S. Wada et al., “Cholesterol-lowering action of BNA-based antisense oligonucleotides targeting PCSK9 in atherogenic diet-induced hypercholesterolemic mice,” Molecular Therapy-Nucleic Acids, vol. 1, article e22, 2012. View at Google Scholar
  8. P. J. White, F. Anastasopoulos, C. W. Pouton, and B. J. Boyd, “Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides,” Expert reviews in molecular medicine, vol. 11, article e10, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Obika, S. M. A. Rahman, A. Fujisaka, Y. Kawada, T. Baba, and T. Imanishi, “Bridged nucleic acids: development, synthesis and properties,” Heterocycles, vol. 81, no. 6, pp. 1347–1392, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Imanishi and S. Obika, “BNAs: novel nucleic acid analogs with a bridged sugar moiety,” Chemical Communications, no. 16, pp. 1653–1659, 2002. View at Google Scholar · View at Scopus
  11. T. P. Prakash, A. Siwkowski, C. R. Allerson et al., “Antisense oligonucleotides containing conformational constrained 2,4-(N-Methoxy)aminomethylene and 2,4- aminooxymethylene and 2-O,4-C-aminomethylene bridged nucleoside analogues show improved potency in animal models,” Journal of Medicinal Chemistry, vol. 53, no. 4, pp. 1636–1650, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. P. P. Seth, C. R. Allerson, A. Berdeja et al., “An exocyclic methylene group acts as a bioisostere of the 2-oxygen atom in lna,” Journal of the American Chemical Society, vol. 132, no. 42, pp. 14942–14950, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. P. P. Seth, A. Siwkowski, C. R. Allerson et al., “Short antisense oligonucleotides with novel 2,4 conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals,” Journal of Medicinal Chemistry, vol. 52, no. 1, pp. 10–13, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. P. P. Seth, G. Vasquez, C. A. Allerson et al., “Synthesis and biophysical evaluation of 2,4-constrained 2O-methoxyethyl and 2,4-constrained 2O-ethyl nucleic acid analogues,” Journal of Organic Chemistry, vol. 75, no. 5, pp. 1569–1581, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Mitsuoka, T. Kodama, R. Ohnishi, Y. Hari, T. Imanishi, and S. Obika, “A bridged nucleic acid, 2,4-BNACOC: synthesis of fully modified oligonucleotides bearing thymine, 5-methylcytosine, adenine and guanine 2,4-BNACOC monomers and RNA-selective nucleic-acid recognition,” Nucleic Acids Research, vol. 37, no. 4, pp. 1225–1238, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Miyashita, S. M. A. Rahman, S. Seki, S. Obika, and T. Imanishi, “N-Methyl substituted 2,4-BNANC: a highly nuclease-resistant nucleic acid analogue with high-affinity RNA selective hybridization,” Chemical Communications, no. 36, pp. 3765–3767, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. S. M. A. Rahman, S. Seki, S. Obika, H. Yoshikawa, K. Miyashita, and T. Imanishi, “Design, synthesis, and properties of 2,4-BNANC: a bridged nucleic acid analogue,” Journal of the American Chemical Society, vol. 130, no. 14, pp. 4886–4896, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. S. K. Singh, R. Kumar, and J. Wengel, “Synthesis of 2-amino-LNA: a novel conformationally restricted high-affinity oligonucleotide analogue with a handle,” Journal of Organic Chemistry, vol. 63, no. 26, pp. 10035–10039, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Honcharenko, O. P. Varghese, O. Plashkevych, J. Barman, and J. Chattopadhyaya, “Synthesis and structure of novel conformationally constrained 1,2-azetidine-fused bicyclic pyrimidine nucleosides: their incorporation into oligo-DNAs and thermal stability of the heteroduplexes,” Journal of Organic Chemistry, vol. 71, no. 1, pp. 299–314, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. E. M. Straarup, N. Fisker, M. Hedtjärn et al., “Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates,” Nucleic Acids Research, vol. 38, no. 20, pp. 7100–7111, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. A. A. Levin, “A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides,” Biochimica et Biophysica Acta, vol. 1489, no. 1, pp. 69–84, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. T. A. Watanabe, R. S. Geary, and A. A. Levin, “Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302),” Oligonucleotides, vol. 16, no. 2, pp. 169–180, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. W. Y. Gao, F. S. Han, C. Storm, W. Egan, and Y. C. Cheng, “Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology,” Molecular Pharmacology, vol. 41, no. 2, pp. 223–229, 1992. View at Google Scholar · View at Scopus
  24. L. Benimetskaya, J. L. Tonkinson, M. Koziolkiewicz et al., “Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent,” Nucleic Acids Research, vol. 23, no. 21, pp. 4239–4245, 1995. View at Google Scholar · View at Scopus
  25. D. A. Brown, S. H. Kang, S. M. Gryaznov et al., “Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding,” Journal of Biological Chemistry, vol. 269, no. 43, pp. 26801–26805, 1994. View at Google Scholar · View at Scopus
  26. M. A. Guvakova, L. A. Yakubov, I. Vlodavsky, J. L. Tonkinson, and C. A. Stein, “Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix,” Journal of Biological Chemistry, vol. 270, no. 6, pp. 2620–2627, 1995. View at Publisher · View at Google Scholar · View at Scopus